Conference Coverage

AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
PUPC Conference Coverage
PUPC Conference Coverage
05/16/2025
Neal Skolnik, MD
In this interview, Neal Skolnik, MD, previews his Practical Updates in Primary Care 2025 presentation on evolving approaches to UTI management, including updated diagnostic guidance, emerging antibiotic...
05/16/2025